Diagnostic Challenges of a MSH2 Variant in Rectal Cancer
Author Information
Author(s): Evaristo Gertruda, Harmath Carla, Segal Jeremy P., Shergill Ardaman, Setia Namrata
Primary Institution: The University of Chicago
Hypothesis
Can a germline MSH2 variant affect the response to immunotherapy in rectal adenocarcinoma?
Conclusion
The study highlights the importance of an integrative approach to assess MMR status for immunotherapy candidacy, even when traditional tests show no deficiency.
Supporting Evidence
- The patient had a germline MSH2 variant classified as a variant of undetermined significance.
- Immunotherapy led to successful disease control over a 33-month follow-up.
- NGS-based identification of microsatellite instability was crucial for treatment decision.
Takeaway
A young woman with rectal cancer had a genetic variant that made her respond well to immunotherapy, even though tests didn't show typical signs of cancer weakness.
Methodology
The study involved genetic sequencing and immunohistochemistry to assess MMR status and tumor characteristics.
Limitations
The absence of functional studies confirming the deleterious effect of the MSH2 variant is a limitation.
Participant Demographics
A 35-year-old female patient with a family history of multiple cancers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website